A review of transplantation immunology is discussed with emphasis on alloantigen presentation, T-lymphoeyte activation and proliferation, and the immune effector mechanisms responsible for allograft rejection, Immunosuppressive pharmacology is introduced beginning with conventional medications (cyclosporine, azathioprine, and corticosteroids) followed by a discussion of drugs recently approved by the US Food and Drug Administration (mycophenolate mofetil, tacrolimus, and the interleukin-2 receptor antagonists). In addition, drugs that are used in the treatment of transplant rejection or as rescue therapy are discussed (muromonab-CD3, antithymocyte globulin, mycophenolate mofetil, tacrolimus, and corticosteroids). Throughout, implications for nurses involved in the pharmacotherapy of transplant recipients are discussed.
Skip Nav Destination
Transplantation| May 01 1999
Overview of Transplantation Immunology and the Pharmacotherapy of Adult Solid Organ Transplant Recipients: Focus on Immunosuppression
Weston W. Bush, PharmD
From the Department of Pharmacy Services, University Hospitals of Cleveland, Ohio.
Reprint requests to Weston W. Hush, PharmD, University Hospitals of Cleveland, Department of Pharmacy Services, B16 Wearn Building, 11100 Euclid Avenue Cleveland, OH AA106.
Search for other works by this author on:
AACN Adv Crit Care (1999) 10 (2): 253–269.
- Views Icon Views
- Share Icon Share
Weston W. Bush; Overview of Transplantation Immunology and the Pharmacotherapy of Adult Solid Organ Transplant Recipients: Focus on Immunosuppression. AACN Adv Crit Care 1 May 1999; 10 (2): 253–269. doi:
Download citation file: